alexa R. Lee Mosley | University of Nebraska Medical Center
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

R. Lee Mosley

Department of Pharmacology and Experimental Neuroscience,  University of Nebraska Medical Center,  USA
Biography

 R. Lee Mosley is a professor and Director of Pharmacology and Experimental Neuroscience department, University of Nebraska Medical Center (UNMC). He has received his BS and MS in microbiology from the University of Oklahoma. In 1992, he graduated as the first PhD candidate from the University of Tulsa's Department of Biology. Dr. Mosley began his postdoctoral career in the Department of Pathology at the University of Michigan Medical Center and Department of Pathology and Experimental Toxicology at Parke-Davis Pharmaceutical Research Division. In 1994, he joined Dr. Richard A. Millerâ's laboratory as an Assistant Research Professor, where he addressed mechanisms of diminished T cell immunity in the aged. In 1998, He currently holds appointments in the CNND, Department of Pharmacology and Experimental Neuroscience, Department of Pathology and Microbiology, and Eppley Cancer Center. His recent research with Dr. Howard Gendelman and graduate student Eric Benner showed in a mouse model of Parkinson's disease (PD) that immune cells induced after immunization with glatiramer acetate (GA), a peptide polymer used to treat multiple sclerosis (MS) patients, significantly protect those neurons that are primarily affected by neurodegenerative processes in PD. This has led to recent investigations addressing the potential of natural regulatory T cells (Treg) in the PD model. Because GA has been shown safe and efficacious in MS patients, Dr. Mosley and the CNND in conjunction with Columbia University implemented clinical trials demonstrating the safety of GA treatments in ALS patients, and have recently initiated studies to evaluate the efficacy of GA and Treg therapeutic regimens in transgenic mice that carry the human SOD1 gene, thus rendering them susceptible to ALS-like neurodegeneration. He has coauthored books and published many research articles in various Prestigious national and international journals.

 

 

 

Research Interest

Mosley’s research interests include Immunoregulation, Neurodegeneration, Neuroprotection, Immunology, Vaccine, T cell, Inflammation, Parkinson's disease, MPTP, Amyotrophic Lateral Sclerosis (ALS, Nanomedicine and Nanotechnology applications in drug therapy

Publications

Active Targeted Macrophage-mediated Delivery of Catalase to Affected Brain Regions in Models of Parkinson's Disease

Yuling Zhao, Matthew J. Haney, Vivek Mahajan, Benjamin C. Reiner, Anna Dunaevsky, R. Lee Mosley, Alexander V. Kabanov, Howard E. Gendelman and Elena V. Batrakova

Research Article: J Nanomed Nanotechnol 2011, S4-003

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords